Abstract: Production of 1,3-butadiene ethanol, that is more than 50% of the total weight of feedstock: A) conversion of feedstock and of ethanol effluent from separation B to a conversion effluent being a majority of 1,3-butadiene, water and ethylene, and to a hydrogen effluent, operating at a pressure between 0.1 and 1.0 MPa, a temperature between 300 and 500° C. in the presence of at least one catalyst; B) separation of conversion effluent originating from A and hydration effluent from C to an ethanol effluent, a butadiene effluent, a water effluent and an ethylene effluent; C) hydration of ethylene fed by ethylene effluent and/or water effluent both from separation B, to produce an ethanol hydration effluent then being recycled to separation B.

Abstract: In an example, a method of butadiene sequestration includes receiving an input stream that includes butadiene. The method includes directing the input stream to a first sulfur dioxide charged zeolite bed for butadiene sequestration via a first chemical reaction of butadiene and sulfur dioxide to form sulfolene.

Abstract: A method for producing olefins comprising (a) introducing to an isothermal reactor a reactant mixture comprising CH4 and O2, wherein the reactor comprises a catalyst bed comprising a catalyst, wherein a catalyst bed temperature is 750-1,000° C., and wherein the reactor has a residence time of 1-100 ms; (b) wherein isothermal conditions minimize hot spots in the bed, thereby decreasing deep oxidation reactions; (c) allowing the reactant mixture to contact the catalyst and react via oxidative coupling of CH4 reaction to form a product mixture comprising C2+ hydrocarbons (olefins and paraffins; C2 hydrocarbons and C3 hydrocarbons) and synthesis gas (H2 and CO), wherein the product mixture has an olefin/paraffin molar ratio of from 0.5:1 to 20:1, and wherein the product mixture has a H2/CO molar ratio of from 0.2:1 to 2.5:1; (d) recovering the product mixture from the reactor; and (e) recovering C2 hydrocarbons and/or synthesis gas from the product mixture.

Abstract: Compounds with fire extinguishing properties having the formula: wherein R1 is —CR5R6R7 or —CR5R6CR8R9R10 as well as fire extinguishing units including one or more of the compounds.

Abstract: Disclosed is (i) a process of making phenol and/or cyclohexanone from cyclohexylbenzene including a step of removing methylcyclopentylbenzene from (a) the cyclohexylbenzene feed supplied to the oxidation step and/or (b) the crude phenol product (ii) a phenol composition and (iii) a cyclohexylbenzene composition that can be made using the process.

Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

Abstract: Disclosed are (i) a process for making cyclohexylbenzene by benzene hydroalkylation with a low methylcyclopentylbenzene selectivity; and (ii) a process of making phenol and/or cyclohexanone from cyclohexylbenzene including a step of removing methylcyclopentylbenzene from the cyclohexylbenzene feed supplied to the oxidation step.

Abstract: The present disclosure relates to methods of removing halides from a reactor effluent comprising treating the halide containing carbonylation product with a resin or material comprising a metal ion with a metal loading of greater than 15 wt % are provided herein. In some aspects, the methods involve treating the halide containing carbonylation product with a silver loaded resin which comprises a loading of greater than 15 wt % of silver to remove inorganic or organic halides.

Abstract: This disclosure relates to a method for continuous recovery of (meth)acrylic acid and an apparatus used for the recovery method. The method of continuous recovery of (meth)acrylic acid according to the present invention may remarkably reduce the amount of extraction solvent used and energy consumption of the total process, and minimize polymerization of (meth)acrylic acid in the recovery process, thus enabling stable recovery of (meth)acrylic acid and operation of a continuous process.

Abstract: To provide a method for recovering an acid of an anionic fluorinated emulsifier with a high yield from a basic ion exchange resin having a nonionic surfactant physically adsorbed thereon and having the anionic fluorinated emulsifier adsorbed thereon. A method for eluting and recovering an acid of an anionic fluorinated emulsifier from a basic ion exchange resin having a nonionic surfactant physically adsorbed thereon and having the anionic fluorinated emulsifier adsorbed thereon, which comprises a step (1) of bringing the basic ion exchange resin into contact with a water-soluble organic solvent and a step (2) of recovering the acid of the anionic fluorinated emulsifier from the basic ion exchange resin from which the ionic surfactant is eluted in the step (1).

Abstract: This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.

Abstract: The present invention relates to the production of (meth)acrylic esters, and more particularly the production of C4-C10 alkyl (meth)acrylates comprising the step of membrane separation dehydration of at least one stream generated during the purification of alkyl (meth)acrylate.

Abstract: Provided is a positive photoresist composition excellent in terms of heat resistance. A radically curable compound is represented by a general formula (1) below (where R1, R2, and R3 each independently represent an alkyl group having 1 to 8 carbon atoms; m and n each independently represent an integer of 1 to 4; p represents an integer of 0 to 4; X, Y, and Z each independently represent an acryloyloxy group, a methacryloyloxy group, or a hydroxy group, and at least one of X, Y, and Z represents an acryloyloxy group or a methacryloyloxy group; and t represents 1 or 2).

Abstract: The present invention relates to a novel ester-based compound, an ester-based composition including the same, a preparation method of the ester-based composition and a resin composition including the ester-based composition as a plasticizer. The ester-based composition according to an embodiment of the present invention is a composition including a novel isophthalate-based ester compound for a plasticizer prepared by a trans-esterification reaction and a composition including the same. A resin composition using the ester-based composition is eco-friendly and has good physical properties such as tensile strength, elongation rate, migration resistance, volatile resistance, etc.

Abstract: The present invention also relates to a process for preparing a diamine/dicarboxylic acid salt wherein the dicarboxylic acid comprises an aromatic dicarboxylic acid and is provided in a powder form; the diamine is provided in a liquid form gradually dosed to the dicarboxylic acid powder, while keeping the dicarboxylic acid powder in constant movement; the processing temperature is above 0° C. and below the boiling temperature of the diamine and the melting temperature of the acid and the salt, and the reaction mixture comprises at most 5 wt. % of water. The present invention also relates to an anhydrous diamine/dicarboxylic acid salt obtainable by the process according to invention, or any embodiment thereof as described above.

Abstract: A process for preparing high molecular weight, branched, acyclic polyalkyleneamines comprising transaminating a reaction mixture that includes at least a first polyalkyleneamine component that contains at least two non-tertiary amine groups separated from one another by a ternary or higher carbon atom and a second polyalkyleneamine component having the formula wherein x, y, and z are the same or different and are integers of from 1 to 10; a, b, c, d, e, and f are the same or different and are H or hydrocarbyl of from 1 to 10 carbon atoms; A, B, C, D, E, are the same or different and are H or hydrocarbyl of from 1 to 10 carbon atoms; provided that at least two of the amine groups are primary or secondary.

Abstract: The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.

Abstract: The present invention relates to omegabalins, which are GABA derivatives of omega-3 fatty acids, and their use in pharmaceutically-acceptable formulations for treating neuropathic pain, fibromyalgia, epilepsy, anxiety, depression, insomnia, Alzheimer's disease, and other neurological conditions.

Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: This present invention discloses a nitro-containing bisoxime ester photoinitiator having a structure represented by general formula (I). This photoinitiator has excellent application performances in terms of storage stability, photosensitivity, developability, pattern integrity, etc., and it has good adaptability to single-wavelength UV-LED light sources and exhibits a photosensitive property, which is obviously superior to those of existing photoinitiators, under the irradiation of UV-LEDs.

Abstract: A bisoxime ester photoinitiator as represented by general formula (I). By introducing a bisoxime ester group and a cycloalkylalkyl group into the chemical structure, this photoinitiator not only has excellent performance in aspects of storage stability, photosensitivity, developability, pattern integrity, and the like, but also exhibits obviously improved photosensitivity and thermal stability compared to similar photoinitiators.

Abstract: The present invention relates to a process for purifying adiponitrile (ADN), wherein crude ADN is introduced into a rectification apparatus (R1). The rectification apparatus (R1) comprises a first side draw and preferably also a second side draw, the first side draw being disposed below the crude ADN introduction point and the optional second side draw being disposed above the crude ADN introduction point. The first side draw is used to draw off a gaseous stream comprising ADN while the optional second side draw is used to draw off undesired by-products such as 1-amino-2-cyanocyclopentene (ACCP) which are often generated in ADN production and consequently may be present in the crude ADN. The gaseous stream from the first side draw of (R1) is introduced into a second rectification apparatus (R2). (R2) is used to separate off ADN from remaining high boilers and any other by-products present, pure ADN being drawn off from (D2) as overhead product.

Abstract: The invention relates to a method for preparing isocyanates by phosgenating the corresponding amines, wherein low-boiling secondary components, excess phosgene, and the co-product hydrogen chloride are separated from the crude liquid isocyanate stream, which is obtained after the phosgenation has occurred, within a maximum of 60 minutes, and wherein the crude liquid isocyanate stream is not exposed to temperatures above 250° C. until said separation.

Abstract: This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Abstract: A urea granulation process with a scrubbing system may involve at least one gaseous waste stream for removal of dust and ammonia whereby the waste stream may be processed through a combination of process steps. In some examples, the process steps may involve washing the dust and ammonia laden stream with water and/or an aqueous urea solution whereby a dust-laden liquid stream and a dust-reduced stream is generated. The process steps may further involve reacting the dust-reduced stream with formaldehyde to form a stream comprising hexamethylenetetramine and urea-formaldehyde and clean off-gas. In some cases, the gas stream may be directed first through the washing step and then through the reacting step.

Abstract: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.

Abstract: There are provided compounds of formula IIb, wherein LG1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Abstract: A positive-type resist composition which generates an acid upon exposure and whose solubility in an alkali developing solution increases under the action of an acid, the composition including a base material component whose solubility in an alkali developing solution increases under the action of an acid; and a compound represented by the following general formula (m0): Z01 to Z04 each independently represent a substituent having electron withdrawing properties, Rb21 and Rb22 each independently represent an alkyl group, an alicyclic hydrocarbon group which may have a substituent, or a hydroxyl group, Rb1 represents an aryl group which may have a substituent, an alkyl group, or an alkenyl group, n1 and n2 represent an integer of 0 to 3, and X0? represents an organic anion.

Abstract: The present invention provides a colored curable resin composition that exhibits good heat resistance and durability in a sputtering process, a cured film, a color filter, a method for manufacturing a color filter, a solid-state image device, an image display device, a compound, and a cation. The colored curable resin composition contains a colorant represented by Formula (1), Formula (2), or Formula (3), a resin, a polymerizable compound, and a polymerization initiator. In Formula (1), R101 and R102 each independently represent a hydrogen atom or a substituent, R103 to R106 each independently represent a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group, R107 to R111 each independently represent a hydrogen atom or a substituent, n1 to n4 each independently represent an integer of 0 to 4, n5 represents an integer of 0 to 6, X represents an anion or is not present, and at least one of R101, . . .

Abstract: The present invention provides novel 2-pyridone compounds and 4-pyridone compounds and methods of treating a subject infected with a pathogen of Staphylococcus aureus, Mycobacterium tuberculosis, Francisella tularensis, Burkholderia pseudomallei, Yersinia pestis, Escherichia coli and Proteus mirabilisone.

Abstract: The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.

Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention provides compounds of formula (I): wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.

Abstract: The present invention is directed to N-acylalkyl prodrugs of nitrogen-containing multi-tyrosine kinase inhibitors. The present invention is further directed to compositions comprising compounds of the invention. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: Provided are 5-(trifluoromethyl)pyrimidine derivatives useful as intermediates for pharmaceuticals and agrochemicals and as intermediates for electronic materials and methods for producing the same. 2,4-dichloro-5-(trifluoromethyl)pyrimidine is reacted with 2,2,2-trifluoroethanol, benzyl alcohol, or benzenethiol to obtain the intended 2-(2,2,2-trifluoroethoxy)-4-chloro-5-(trifluoromethyl)pyrimidine, 2-benzyloxy-4-chloro-5-(trifluoromethyl)pyrimidine, 2,4-bis(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)pyrimidine, or 2-chloro-4-phenylthio-5-(trifluoromethyl)pyrimidine.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3, and X1 to X6 are the same as defined in Claim 1.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: The present invention is directed to a new impurity of famotidine, process for preparing and isolating it. The invention is further related to analytical methods of its identification, synthesis and characterization.

Abstract: The invention relates to a process for transformation of lignocellulosic biomass or cellulose using in a simultaneous manner an original combination of at least two homogeneous catalysts and one or more heterogeneous catalyst(s). The use of these catalysts makes it possible to obtain mono-oxidized or poly-oxidized upgradable products directly and to limit the formation of non-upgradable products. Non-upgradable products are defined as soluble and non-soluble humins, i.e., products of high molecular weight obtained from undesirable condensation reactions of sugars and their derivatives.

Abstract: Provided is a compound represented by formula I, wherein R9 is a C1-C22 hydrocarbyl group, or a C2-C3 ester-substituted C1-C3 alkyl group, R5, R6, R7, and R8 are alkyl groups or H, and R1, R2, R3, and R4 are H or a lower hydrocarbyl group. Or, R9 is a C2-C22 hydrocarbyl group, or a C2-C3 ester-substituted C1-C3 alkyl group, and R5 is connected to R1, R6 is connected to R2, R7 is connected to R3, R8 is connected to R4 to form six-membered rings. The present compound is temperature-sensitive and can enter into cells. An intracellular temperature distribution image having high spatial and temporal resolution can thus be obtained. The present compound can also perform distribution calibration on a temperature-sensitive fluorescent compound. Also provided is a method for measuring temperature distribution within a living cell, and a corresponding detection kit. The method satisfies the requirements of small size measurement and rapid measurement, thereby achieving high resolution in terms of space and time.

Abstract: Compounds of formula (9), which are useful as therapeutic drugs for diabetes, may be produced by the following reaction sequence: (a) diester (3) is synthesized by the reaction of compound (1) and compound (2); (b) ester (4) is synthesized by deprotection of diester (3) (or ester (4) is synthesized by the reaction of compound (5) and compound (2)); (c) ester (4) is converted to acid halide; (d) the acid halide is reacted with an amidinophenol derivative; and (e) the obtained diester derivative is deprotected under acidic conditions, and converted to compound (9): wherein R1 is a halogen atom, R4 is a lower alkyl group, R5 is a lower alkyl group, and R12 is a hydrogen atom or a halogen atom.

Abstract: Compounds of formula (VI), which are useful as therapeutic drugs for diabetes, may be produced by reacting a compound of formula (II) with an acid halogenating agent to give an acid halide; reacting the acid halide with a compound of formula (IV) in the presence of a base, and crystallizing compound (V) or a salt thereof from the reaction system; and subjecting the compound of formula (V) to reductive deprotection in the presence of a metal catalyst, and crystallizing the compound of (VI) or a salt thereof from the reaction system:

Abstract: In an example, a method of butadiene sequestration includes receiving an input stream that includes butadiene. The method includes directing the input stream to a first sulfur dioxide charged zeolite bed for butadiene sequestration via a first chemical reaction of butadiene and sulfur dioxide to form sulfolene.

Abstract: The invention discloses a process for the preparation of Zileuton of formula I by employing acetic acid-1-benzo[b]thiophen-2-yl-ethyl-ester of formula-III as an intermediate.

Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

Abstract: The present invention relates to a process for the preparation of efinaconazole.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof